Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy
Authors
Keywords
-
Journal
CELLULAR AND MOLECULAR LIFE SCIENCES
Volume 79, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-12-30
DOI
10.1007/s00018-021-04089-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- T cell circuits that sense antigen density with an ultrasensitive threshold
- (2021) Rogelio A. Hernandez-Lopez et al. SCIENCE
- CD38 Multi-Functionality in Oral Squamous Cell Carcinoma: Prognostic Implications, Immune Balance, and Immune Checkpoint
- (2021) Zhuang Ding et al. Frontiers in Oncology
- Efficiency and side effects of anti-CD38 CAR T cells in an adult patient with relapsed B-ALL after failure of bi-specific CD19/CD22 CAR T cell treatment
- (2020) Yelei Guo et al. Cellular & Molecular Immunology
- Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib
- (2020) Jim S. Qin et al. JOURNAL OF IMMUNOTHERAPY
- Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).
- (2020) Caron A. Jacobson et al. JOURNAL OF CLINICAL ONCOLOGY
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Engineering CAR-T Cells for Next-Generation Cancer Therapy
- (2020) Mihe Hong et al. CANCER CELL
- Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies
- (2020) Árpád Szöőr et al. CANCER LETTERS
- Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial
- (2020) Yang Liu et al. CYTOTHERAPY
- Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides
- (2020) Preeti Sharma et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
- (2020) Estefanía García-Guerrero et al. Frontiers in Immunology
- CAR-T design: Elements and their synergistic function
- (2020) Jayapriya Jayaraman et al. EBioMedicine
- Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
- (2020) Bassel Nazha et al. Frontiers in Oncology
- A rational mouse model to detect on-target, off-tumor CAR T cell toxicity
- (2020) Mauro Castellarin et al. JCI Insight
- Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.
- (2020) M.-L. Schubert et al. ANNALS OF ONCOLOGY
- Engineering Next-Generation CAR-T Cells for Better Toxicity Management
- (2020) Alain E. Andrea et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma – assessing tumor and T cell interaction
- (2020) Jatuporn Sujjitjoon et al. Translational Oncology
- CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
- (2019) Mohamad Hamieh et al. NATURE
- Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells
- (2019) Esther Drent et al. CLINICAL CANCER RESEARCH
- Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells
- (2019) Zhitao Gao et al. Journal of Genetics and Genomics
- Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
- (2019) Shengnan Yu et al. Molecular Cancer
- Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
- (2019) Sara Ghorashian et al. NATURE MEDICINE
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy
- (2019) Sarwish Rafiq et al. Nature Reviews Clinical Oncology
- Treatment of Transient Peripheral Neuropathy During Chimeric 14.18 Antibody Therapy in Children With Neuroblastoma
- (2018) Pranathi Ari et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
- (2018) Margherita Norelli et al. NATURE MEDICINE
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
- (2018) Theodoros Giavridis et al. NATURE MEDICINE
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oxidative stress preconditioning of mouse perivascular myogenic progenitors selects a subpopulation of cells with a distinct survival advantage in vitro and in vivo
- (2018) Cesare Gargioli et al. Cell Death & Disease
- Neurotoxicity Associated with a High-Affinity GD2 CAR—Response
- (2018) Sarah A. Richman et al. Cancer Immunology Research
- Neurotoxicity Associated with a High-Affinity GD2 CAR—Letter
- (2018) Robbie G. Majzner et al. Cancer Immunology Research
- Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions.
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
- (2018) Elena J. Orlando et al. NATURE MEDICINE
- Daratumumab induces CD38 internalization and impairs myeloma cell adhesion
- (2018) Jayeeta Ghose et al. OncoImmunology
- Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors
- (2018) Giulia Golinelli et al. CANCER GENE THERAPY
- Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
- (2018) Judith Feucht et al. NATURE MEDICINE
- CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
- (2018) Stephanie Vairy et al. Drug Design Development and Therapy
- CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors
- (2018) Anna C. Filley et al. Frontiers in Oncology
- A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
- (2017) Esther Drent et al. MOLECULAR THERAPY
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
- (2017) Frederick L. Locke et al. MOLECULAR THERAPY
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
- (2017) Sarah A. Richman et al. Cancer Immunology Research
- Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview
- (2016) C. H. J. Lamers et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
- (2016) Inger S. Nijhof et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
- (2016) Kole T. Roybal et al. CELL
- Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer
- (2016) Kaichao Feng et al. Science China-Life Sciences
- EGFR as a Pharmacological Target in EGFR -Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?
- (2016) E-->-E -->Ke et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
- (2015) X. Liu et al. CANCER RESEARCH
- Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity
- (2015) H. G. Caruso et al. CANCER RESEARCH
- CAR therapy: the CD19 paradigm
- (2015) Michel Sadelain JOURNAL OF CLINICAL INVESTIGATION
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
- (2015) E. Sotillo et al. Cancer Discovery
- Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
- (2014) Shannon L. Maude et al. CANCER JOURNAL
- CD38 is highly expressed and affects the PI3K/Akt signaling pathway in cervical cancer
- (2014) SHAN LIAO et al. ONCOLOGY REPORTS
- Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
- (2013) M. Hudecek et al. CLINICAL CANCER RESEARCH
- Design and development of therapies using chimeric antigen receptor-expressing T cells
- (2013) Gianpietro Dotti et al. IMMUNOLOGICAL REVIEWS
- High throughput solution-based measurement of antibody-antigen affinity and epitope binning
- (2013) Patricia Estep et al. mAbs
- PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
- (2013) V. D. Fedorov et al. Science Translational Medicine
- Cardiac side effects of trastuzumab in breast cancer patients – single centere experiences
- (2013) Joanna Huszno et al. Wspolczesna Onkologia-Contemporary Oncology
- The Basic Principles of Chimeric Antigen Receptor Design
- (2013) Michel Sadelain et al. Cancer Discovery
- Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
- (2012) Christopher C Kloss et al. NATURE BIOTECHNOLOGY
- EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects
- (2011) Rolando Perez et al. Cancers
- HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors
- (2010) N. Ahmed et al. CLINICAL CANCER RESEARCH
- Evidence for a TCR Affinity Threshold Delimiting Maximal CD8 T Cell Function
- (2010) D. A. Schmid et al. JOURNAL OF IMMUNOLOGY
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- (2010) Alice L. Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activated T–cell-mediated Immunotherapy With a Chimeric Receptor Against CD38 in B-cell Non-Hodgkin Lymphoma
- (2009) Keichiro Mihara et al. JOURNAL OF IMMUNOTHERAPY
- Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression
- (2009) Nabil Ahmed et al. MOLECULAR THERAPY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started